| Business Summary | | ZymeTx,
Inc.
is
a
biotechnology
company
engaged
in
the
discovery,
development
and
commercialization
of
products
used
to
diagnose
and
treat
viruses.
ViraZyme,
the
Company's
core
technology,
exploits
the
subtle
structural
differences
and
characteristics
of
enzymes
to
create
products
used
to
diagnose
and
treat
viral
diseases.
The
initial
viral
targets
of
the
Company's
diagnostic
products
are
respiratory
infections
including
influenza
A
and
influenza
B,
respiratory
syncytial
virus
or
RSV,
parainfluenza
and
adenovirus.
RSV
infects
humans,
usually
children,
and
is
an
important
cause
of
acute
respiratory
disease.
Adenovirus
can
cause
respiratory
disease,
keratoconjunctivitis,
diarrhea,
cystitis
and
other
diseases. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | ZMTX
is
a
development
stage
biotechnology
company
engaged
in
the
discovery,
development
and
commercialization
of
unique
products
for
the
diagnosis
and
treatment
of
viruses.
For
the
nine
months
ended
3/31/01,
revenues
decreased
33%
to
$832
thousand.
Net
loss
increased
2%
to
$4.1
million.
Revenues
reflect
the
effects
of
a
mild
influenza
season.
Net
loss
also
reflects
higher
R&D
expenses
due
to
a
decrease
in
the
reimbursement
of
research
expenditures. | More
from
Market Guide: Significant
Developments |
| | | James
R. Tolbert
III,
Chmn. Norman
R. Proulx,
Pres./CEO Fred
Hiller,
Acting
CFO Craig
D. Shimasaki
Ph.D.,
VP. | More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|